APA (7th ed.) Citation

Lin, M., Chu, K., Chen, C., Jiang, Y., Hong, W., Hung, M., & Hsu, C. (2026). Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study. Cancer Medicine, 15(5), 1. https://doi.org/10.1002/cam4.71881

Chicago Style (17th ed.) Citation

Lin, Min‐Hsi, Kuo‐An Chu, Chiu‐Fan Chen, You‐Cheng Jiang, Wei‐Cheng Hong, Ming‐Yen Hung, and Chun‐Hsiang Hsu. "Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study." Cancer Medicine 15, no. 5 (2026): 1. https://doi.org/10.1002/cam4.71881.

MLA (9th ed.) Citation

Lin, Min‐Hsi, et al. "Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study." Cancer Medicine, vol. 15, no. 5, 2026, p. 1, https://doi.org/10.1002/cam4.71881.